>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its binding ability in a functional ELISA. When Recombinant Mouse LILRB4/CD85k/ILT3 is coated onto a microplate at 2 μg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7
binds with a typical ED50 = 20-120 ng/mL.
Mouse myeloma cell line, NS0-derived mouse LILRB4/CD85k/ILT3 protein Gly24-Lys238, with a C-terminal 6-His tag
When Recombinant Mouse LILRB4/CD85k/ ILT3 is coated onto a microplate at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7 (Catalog # 914-AN) binds with a typical ED50 of 20-120 ng/mL.
LILRB4, also known as ILT3, CD85k, and LIR-5, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation (1). Mature mouse LILRB4 consists of a 215 amino acid (aa) extracellular domain with two Ig-like domains, a 22 aa transmembrane segment, and a 75 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2). Within the ECD, mouse LILRB4 shares 45% and 77% aa sequence identity with human and rat LILRB4, respectively. Alternative splicing of mouse LILRB4 generates a potentially soluble isoform that lacks the transmembrane segment (2). LILRB4 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC) (3, 6, 7). Ligation of LILRB4 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection (3, 5, 8, 9). Soluble LILRB4 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL (5, 8, 10). In turn, CD8+ Ts cells induce LILRB4 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC (6, 7, 9, 11, 12).
Vlad, G. et al. (2010) Int. Rev. Immunol. 29:119.
Castells, M.C. et al. (1994) J. Biol. Chem. 269:8393.
Cella, M. et al. (1997) J. Exp. Med. 185:1743.
Heinzmann, A. et al. (2000) Eur. J. Immunogenet. 27:121.
Suciu-Foca, N. et al. (2007) J. Immunol. 178:7432.
Gleissner, C.A. et al. (2007) Eur. J. Immunol. 37:177.
Manavalan, J.S. et al. (2004) Int. Immunol. 16:1055.
Vlad, G. and N. Suciu-Foca (2012) Exp. Mol. Pathol. 93:294.
Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
Vlad, G. et al. (2006) Int. Immunopharmacol. 6:1889.
Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
Brenk, M. et al. (2009) J. Immunol. 183:145.
Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 4
Entrez Gene IDs:
11006 (Human); 14728 (Mouse)
CD85 antigen-like family member K; CD85k antigen; CD85k; HM18; ILT3; ILT-3; ILT3CD85K; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LILRB4; LIR5; LIR5LILRB5; LIR-5subfamily B, member 4; member 4
Have you used Recombinant Mouse LILRB4/CD85k/ILT3 Protein, CF?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.